Daily Stock List
Centor, Inc. (CNTO)
We are highlighting Centor, Inc. (CNTO) today, here at the QualityStocks Daily Newsletter.
Centor, Inc. is a gold exploration and development company with headquarters in Winter Park, Florida. The Company focuses on the discovery of hard rock reserves and the development of alluvial mining. In 2012, Centor purchased the 40.2 sq km Nobewam Concession situated on the world famous Ashanti Gold Belt. The Nobewam Concession is 30 minutes from Ghana's second largest city of Kumasi. The Ashanti Belt hosts many of the industry's major and mid-tier firms.
Centor Resources, Inc. Ghana Ltd. is a wholly owned subsidiary of Centor. Centor Resources will manage the day-to-day mining operations and oversee testing operations. The Nobewam permit regionally lies on the western flank of the Ashanti belt and within the Kumasi basin. Concerning the Nobewam permit geology, a systematic exploration program over this permit highlights a consistent 10 km strike length and 4 km wide Au anomaly that the Company believes is worthy of follow up.
At the end of April, Centor announced that they commenced gold exploration and mining operations focused on the discovery of hard rock reserves and the development of alluvial mining operations in Ghana, West Africa. Centor believes that Ghana offers major opportunities for long-term profitability. In addition, as of April 24, 2013, they finalized an option agreement to purchase Achaa Mining, a Ghanaian company. The acquisition of Achaa will provide Centor an additional concession of 26.67 square kilometers within the Ashanti Gold Belt.
Earlier this month, Centor announced the acquisition of 100 percent interest in the Nobewan Gold Concession in Ghana, West Africa from Bullnet Gold Resources. With this agreement, the Company obtains testing already completed by Newmont on the Concession including soil geochemistry, VLF, electromagnetics and geological mapping.
These indicate well-defined magnetic banding and high anomalies at the northeastern and southwestern portion of the concessions that warrant further testing. Centor is planning to begin an immediate testing program to refine identified target areas further. This includes a 1.8 km strike zone observed in the central portion of the concession.
Centor, Inc. (CNTO), closed Tuesday's session at $1.06, up 6.00%, on 61,300 volume with 39 trades. The average volume for the last 60 days is 13,146 and the stock's 52-week low/high is $0.025/$1.15.
Technologies-Scan Corp. (TENP)
PennyStocks24 reported today on Technologies-Scan Corp. (TENP), Otcstockexchange, Whisper from Wall Street, Hot Stock Profits, The Stock Scout, PennyStockPlayers, PennyStockClub, Penny Stock Pros did last week, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Technologies-Scan Corp. is a development stage enterprise with corporate headquarters in Labelle, St-Jerome, Province of Quebec. The Company's plan of operation is selling and distributing health products, including a health database system. Technologies-Scan has developed an extensive database and software for natural health products. The Company's shares trade on the OTCQB.
Technologies-Scan has their Medicus21 software. This is an innovative information provider of natural health products for use by way of a mobile application and barcode reader. Medicus21 software enables the user to scan any natural health product's bar code, through the help of their smart phone, and immediately obtain all nutritional information, use, benefits and a host of information on the product.
Technologies-Scan's Joint Venture with Social Geek Media (SGM) includes the design, technologies, how to, development, production and sale of nutritional, protein and dietary supplements online. In addition, to SGM, Technologies-Scan's partners include Amazon Web Services and Groupon.
Today, Technologies-Scan announced the signing of an exclusive definite sales, marketing and commercialization agreement with Social Geek Media (SGM) for their Proteina21 weight loss product line. Technologies-Scan owns an exclusive distribution, sales and marketing license for Proteina21 weight loss products for the United States market and options for the Canadian and European markets. Proteina21 is a product line of food supplements and readymade meals high in protein and low in carbohydrates. The design of this product line is to help people lose weight.
Ghislaine St-Hilaire, Technologies-Scan's Chief Executive Officer, said," "Our due diligence was thorough and quick on the letter of intent we signed earlier last week, both parties worked extremely hard on getting it done quickly so to start sales as soon as possible. The company is thrilled at the prospect of getting to work on sales of this great product line in the US. The US boasts a 66 billion dollar weight loss market and we want a part of it."
Technologies-Scan Corp. (TENP), closed Tuesday's trading session at $0.064, up 12.28%, on 2,288,093 volume with 130 trades. The average volume for the last 60 days is 11,994 and the stock's 52-week low/high is $0.05/$0.243.
Fission Uranium Corp. (FCU.V)
Today we are highlighting Fission Uranium Corp. (FCU.V), here at the QualityStocks Daily Newsletter.
Fission Uranium Corp. is a resource company that specializes in the strategic acquisition, exploration and development of uranium properties. The Company has a significant discovery at Patterson Lake South (PLS) in Canada's Athabasca Basin. Fission holds additional properties on the Western side of the Athabasca Basin and in the emerging uranium district of Macusani in Peru. Fission Uranium has their headquarters in Kelowna, British Columbia.
The Athabasca Basin is home to the world's richest source of high-grade uranium. Fission Uranium is the Operator of the PLS exploration project. This project is a 50/50 Joint Venture (JV) held with Alpha Minerals, Inc. PLS is a high-grade, shallow-depth uranium discovery.
In addition, Fission has their Patterson Lake North project. This project is 27,408 ha. It is approximately 30 km south of the UEX/AREVA Anne and Collette uranium deposits near Shea Creek. The Company also has their Clearwater West project. This consists of three contiguous claims in the same NE-SW-oriented magnetic low corridor as the PLS high-grade discovery.
Furthermore, Fission has their North Shore project. This project's location is along the northwest margin of the Athabasca Basin. It is approximately 10 km SW of Cameco's Maurice Bay Uranium Deposit. Additionally, in Macusani, Peru, Fission has nine claim blocks covering 51 square km located within an emerging uranium district in southeastern Peru.
Yesterday, Fission Uranium (the Operator) and their 50 percent Joint Venture partner, Alpha Minerals, reported assay results from three additional drill holes within Zone R00E at their Patterson Lake South (PLS) property. They also reported results from two regional tests.
Results on the R00E Zone show high-grade mineralization at shallow depth in the east and west section. Hole PLS13-059 returned two mineralized intervals. This includes 9.5m @ 17.78 percent U3O8 within 20.5m at 8.57 percent U3O8. With a Grade x Thickness (GT) value of 175.7 for this interval, this is now the Zone's best mineralized hole to date. This surpasses hole PLS13-043: 22.0m at 4.8 percent U3O8.
Fission Uranium Corp. (FCU.V), closed Tuesday's trading session at $0.68, down 4.23%, on 458,580 volume. The stock's 52-week low/high is $0.52/$0.73.
Location Based Technologies, Inc. (LBAS)
StockMister, Your Stock Alert, The Stock Brainiac, Stock Edge, and Penny Stock SMS Publisher reported earlier on Location Based Technologies, Inc. (LBAS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Based in Irvine, California, Location Based Technologies, Inc. designs and builds dedicated GPS products and services. Their consumer products sell under the PocketFinder brand; their commercial products sell under the LBT brand. The Company generates revenue by selling their products and charging customers an ongoing service fee. Location Based Technologies offers monthly and annual subscription plans. All of their devices are made in the United States.
The Company designs, develops, and sells Consumer and Commercial GPS tracking solutions based on the global GSM network. The primary intention of Consumer products are to be used by people who need to locate portable assets, vehicles, pets, and other people who are unable to use a cell phone to communicate their location. This includes children, seniors or people with special needs. The marketing of Commercial products are to businesses of all sizes and governmental organizations that need to track vehicles, mobile equipment, portable assets and workers.
The Company offers their Personnel Tracking Device. Personal GPS Trackers provide a long-term tracking solution that allows one to locate, track and manage mobile personnel from their office or out in the field with the free mobile apps for iOS and Android. Location Based Technologies also has their Asset Tracking Device. The GPS Asset Tracker is a long-term battery powered tracking device. It provides complete control over fixed and portable assets and equipment.
In addition, the Company offers their Vehicle Tracking Device. This is a GPS vehicle-tracking device that lets one track and manage a single vehicle or an entire fleet from their website or their Smartphone with the free mobile app for iOS and Android.
Recently, Location Based Technologies announced that they received payment for a second order of PocketFinder devices from Parsis Cia Ltda. A third order from Parsis is in process and the Company anticipates receiving a fourth order within the next 90 days. Parsis has indicated their intention to purchase 800 units before June 2013. They believe the market opportunity in Ecuador for PocketFinder and LBT products will continue to grow considerably.
Last week, Location Based Technologies announced that the Company received a 5 star product review for their PocketFinder personal locator from MacReview.com. This review highlights the PocketFinder device features and validates that the PocketFinder iOS App is, "One of the most comprehensive apps of this type we've ever seen." MacReview.com has become the most trusted and dependable Mac resource on the web.
Location Based Technologies, Inc. (LBAS), closed Tuesday's trading session at $0.15, down 6.25%, on 237,295 volume with 22 trades. The average volume for the last 60 days is 135,383 and the stock's 52-week low/high is $0.12/$0.48.
North Bay Resources, Inc. (NBRI)
FeedBlitz and Stock Guru reported earlier on North Bay Resources, Inc. (NBRI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
North Bay Resources, Inc. is a junior mining company that lists on the OTC Markets' OTCQB. Their corporate mission is to build a portfolio of viable mining prospects worldwide and develop them by way of subsidiaries and Joint Venture (JV) partners to their full economic potential. North Bay Resources is based in Skippack, Pennsylvania.
The basis of the Company's business plan is the Generative Business Model. The design of this is to leverage their properties into near-term revenue streams even during the earliest stages of exploration and development. They accomplish this by entering into sales, JV, and/or option contracts with other mining companies, for which the Company generates revenue via payments in cash, stock, and other consideration.
The Company has more than 150 mineral and placer claims encompassing approximately 60,000 acres throughout the Province of British Columbia. In the United States, North Bay Resources owns the Ruby Gold Mine in Sierra County, California. The Company is currently looking to acquire additional operating mines in the western United States.
North Bay Resources looks to acquire, develop, and exploit natural resource properties with extensive reserves of precious metals, including gold, silver, platinum, and palladium, and base metals, including copper, zinc, lead, molybdenum, and others. The Company expects to generate long-term revenue from their acquisition of the Ruby Mine, through the acquisition of additional mines, and by the development of their properties, either independently or through JV partners, into operating mines.
The Ruby Mine, a/k/a the Ruby Gold Project, is a fully permitted underground placer and lode mine located near Downieville in Sierra County. The Ruby Property encompasses approximately 1,755 acres. The property consists of the subsurface mineral rights of two patented claims totaling approximately 435 acres and 30 unpatented claims containing approximately 1,320 acres.
At the end of April, North Bay Resources confirmed that operations at the Ruby Mine resumed on schedule on April 29, 2013. They additionally announced that their wholly owned subsidiary, Ruby Gold, Inc. (RGI) leased new and expanded office space in Grass Valley, California. This will serve as the Ruby Mine's year-round mine planning and coordination headquarters.
North Bay Resources, Inc. (NBRI), closed Tuesday's trading at $0.06, up 25.26%, on 1,191,118 volume with 77 trades. The average volume for the last 60 days is 315,481 and the stock's 52-week low/high is $0.029/$0.13.
ScripsAmerica, Inc. (SCRC)
SecretStockPromo, StockOnion, Penny Pick Finders, PennyStockProphet, Buzz Stocks, and PlanetPennies reported earlier on ScripsAmerica, Inc. (SCRC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in New Castle, Delaware, ScripsAmerica, Inc. delivers pharmaceutical products to a wide spectrum of end users across the health care industry through the largest pharmaceutical distributor in North America, McKesson Corp. End users include physicians' offices, retail pharmacies, long-term care sites, hospitals, and Government and home care agencies. ScripsAmerica's shares trade on the OTC Market's OTCQB.
ScripsAmerica provides a strong low cost system of broad based U.S. national marketing, sales, and distribution of generic Rx, branded Rx, Over-the-Counter (OTC), nutraceuticals, and oral delivery OTC pharmaceuticals. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. ScripsAmerica's other customers include Cardinal Health, Curtis Pharmaceuticals, MedVet and the United States Veterans Administration.
For Consumers, ScripsAmerica's mission is to provide them the same high quality pharmaceutical, vitamin, and nutritional supplements that they supply nationally to Hospitals & Nursing Homes. Concerning Pharmaceutical Contract Services, the Company's service offering includes fulfilling prescription and OTC orders, labeling, packaging, as well as shipping.
ScripsAmerica has their RapiMed® product line. They created RapiMed® for children who have difficulties swallowing medication, and for parents who are tired of measuring cups and syringes. RapiMed® products are easy to administer; they are rapid dissolving, precise dosage, individually wrapped childproof packages, and easy to carry around.
The Company's Pediatric "RapiMed®" will compete with other children’s analgesic products. ScripsAmerica anticipates project completion with market rollout scheduled for this year. RapiMed® formulation is compatible for use in the development of Oral Delivery Technology products to treat Migraines, Sleep Deprivation, Allergies, and Vitamin Deficiencies.
Last week, ScripsAmerica announced that the Company is in expansion funding negotiations with a Hong Kong investment banking syndicate. Funding commitments will enable ScripsAmerica to pursue acquisition and joint venture opportunities aggressively, in the United States and Asia.
Mr. Bob Schneiderman, ScripsAmerica's Chief Executive Officer, said, "We are very excited to announce our funding negotiations and the incredible potential for ScripsAmerica. The funding will not only allow the Company to pursue acquisition opportunities, but additionally will provide the capital to aggressively launch our RapiMed® product line."
ScripsAmerica, Inc. (SCRC), closed at $0.18, up 13.92%, on 183,069 volume with 29 trades. The average volume for the last 60 days is 74,109 and the stock's 52-week low/high is $0.1111/$0.51.
Telkonet, Inc. (TKOI)
SmallCapVoice and FeedBlitz reported earlier on Telkonet, Inc. (TKOI), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Telkonet, Inc. is a leading energy management technology provider. The Company offers hardware, software and services to commercial customers around the world. Their business divisions include EcoSmart, the energy management platform featuring the EcoCentral cloud-based management service and Recovery Time™ technology. The Company's business divisions also include EthoStream, one of the largest high-speed Internet access (HSIA) providers in the world. Telkonet has their corporate headquarters in Milwaukee, Wisconsin.
The Company's EcoSmart family of products includes EcoInsight and EcoWave intelligent thermostats, the EcoGuard energy management outlet and the EcoSwitch energy-efficient light switch. These can undergo deployment in most building environments to cut utility costs and enable remote monitoring and control using the EcoCentral management platform.
Their EcoInsight is a programmable controllable thermostat. It has more than 125 configurable settings used to control the efficiency of HVAC systems. The Company's EcoView In-Room Occupancy Sensor is a passive infrared (PIR) detector, which evaluates body temperature and motion to ensure accurate occupancy detection.
Telkonet's EcoWave Remote Thermostat Package solution consists of two hardware components. These are the wireless EcoAir battery powered display unit and the EcoSource HVAC controller. The EcoSource is placed in the HVAC unit for physical control of the system. Their EcoContact (infrared occupancy control) is a motion sensor and magnetic contact equipped with ZigBee Standard Power for wireless operation.
Telkonet's energy management products can reduce energy consumption, minimize carbon footprints and help eliminate the need for the construction of new power plants.
In mid-May, Telkonet announced their 2013 first quarter financial results. They recorded a 62 percent increase in revenue because of the continuing growth of their energy management technology solutions. They had Revenue of $3.1 million in comparison to $1.9 million for the quarter ended March 31, 2012.
Recently, Telkonet announced that Mr. Jason Tienor, President and Chief Executive Officer, is scheduled to present at the SeeThruEquity Second Annual Investor Conference on June 4, 2013 at The Penn Club in New York, New York. Mr. Tienor will be providing a corporate overview and will be available for one-on-one meetings with investors and analysts. SeeThruEquity, LLC is an investment research and corporate access firm. They create high quality research reports on small- and micro-cap companies with less than $1 billion in market capitalization.
Telkonet, Inc. (TKOI), closed Tuesday's trading session at $0.25, up 13.64%, on 175,455 volume with 36 trades. The average volume for the last 60 days is 174,134 and the stock's 52-week low/high is $0.117/$0.34.
GroveWare Technologies Ltd. (GROV)
PennyStocks24, Information Solutions Group, Bird Gang Stocks, GoldminePennyStocks, WallstreetSurfers, CashMoneyPlays, Stocktwiter, and Penny Dreamers reported earlier on GroveWare Technologies Ltd. (GROV), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Based in Toronto, Ontario, GroveWare Technologies Ltd. is one of North America's leading providers of mobile solutions to enterprise. The Company specializes in the rapidly growing Mobile Business Process Management (BPM) marketplace. GroveWare has developed an advanced e-form-centric mobile application, "MobiTask™" for use with all the mainstream wireless operating systems used by Smartphones and tablets. GroveWare Technologies lists on the OTCQB.
The Company is specifically targeting the government, construction, healthcare, and law enforcement sectors. Their MobiTask™ mobilizes employee tasks in the field and connects them directly to the organization's enterprise software systems. MobiTask™ allows organizations to deploy mobile solutions for workers in transit, fast, as well as cost-effectively. MobiTask works on all mainstream wireless operating systems. These include Apple iOS©, Android™, BlackBerry® and Windows Mobile©.
MobiTask™ provides the convenience of using dynamic electronic forms created using GroveWare's eXFORMA™ middleware to collect field data; manage workflow, HR and CRM tasks wirelessly; store documents locally, and it integrates quickly with most ERP systems and back-end databases on any application. Users can remotely and wirelessly clock-in/out, and approve and initiate workflow tasks, or use dynamic e-Forms for inspections, licensing and data collection all from their Smartphones.
GroveWare Technologies' eXFORMA™ is a business process automation platform. eXFORMA™ enables organizations to develop web based service delivery applications, efficiently, which integrate with their ERP investments simply, easily and without the need for programming. The basis of all of the Company's products are on their proprietary software – the eXFORMA BPM Suite. Packaged and integrated inside eXFORMA are an advanced e-form creator and manager, a sophisticated workflow engine, a calendar and resource manager, extensive mobility modules and tools, a document management system, and a premier reporting application.
For business users, it provides a user-friendly browser-based interface for quickly building robust electronic forms that can automate business processes. For the Information Technology (IT) professional, it provides a powerful forms engine that can be plugged into company-wide portals to serve up electronic processes throughout an enterprise.
GroveWare Technologies Ltd. (GROV), closed Tuesday's trading session at $0.0697, up 4.03%, on 1,000 volume with 1 trade. The average volume for the last 60 days is 117,286 and the stock's 52-week low/high is $0.0502/$10.00.
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.0938, up 4.22%, on 135,984 volume with 239 trades. The stock’s average daily volume over the past 60 days is 525,232, and its 52-week low/high is $0.0618/$0.28.
Cardium Therapeutics, Inc. announced today that Institutional Shareholder Services, Inc. and Glass, Lewis & Co., LLC, the leading independent U.S. proxy advisory firms, each recommend that Cardium's stockholders vote "FOR" all proposals in the proxy statement and reccomend a "1 Year" advisory say on pay frequency with respect to the matters that will be considered at the Company's upcoming annual meeting scheduled for June 6, 2013. CEO of CXM, Christopher J. Reinhard, was pleased that the top independent proxy and corporate governance advisory firms (whose recommendations are relied upon by institutional shareholders), have recommended in favor of all proposals contained in the company's recent proxy statement.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Announces Favorable Recommendations From ISS And Glass Lewis For Annual Meeting Proposals
Cardium Announces Generx Publication In Molecular Therapy
Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
DoMark Internatioxnal, Inc. (DOMK)
The QualityStocks Daily Newsletter would like to spotlight DoMark International, Inc. (DOMK). Today, DoMark International, Inc. closed trading at $0.076, up 1.33%, on 115,568 volume with 2 trades. The stock’s average daily volume over the past 60 days is 164,173, and its 52-week low/high is $0.0322/$3.18.
DoMark International, Inc. offered markets an update today on the company's operations and future plans in the extremely hot smartphone and tablet accessory space, ranging from their 100% owned IRCharger technology set to launch Aug 1 for Apple iPhones and Samsung Galaxy III and S4, to the purchase of a 29% ownership stake in developer Imagic Ltd. Also of note was the planned divestment of the Barefoot Science unit and appointment of global entrepreneur and industrialist, John Bentley, as a Non-Executive Director this coming June.
DoMark International, Inc. (DOMK) is focused on researching, evaluating, and acquiring profitable private firms in the business segments of sports, technology, medical, energy, and business services. By providing the financial and human capital necessary to deal with overwhelming administrative, planning, governance, compliance, and regulatory challenges, its newly acquired partners can focus their energy and flourish.
Through its wholly owned subsidiary, SolaWerks, Inc., DoMark is committed to revolutionizing the efficiency and capabilities of a new generation of mobile devices. The subsidiary's current focus is on developing and distributing the SolaPad, a combined cover and charging system for Apple's iPad, and the SolaCase, a combined cover and charging system for all versions of Apple's iPhone.
Musclefoot, Inc., another wholly owned subsidiary of DoMark, is engaged in the distribution, marketing, and sale of Barefoot Science, the revolutionary patented foot care system designed to relieve foot and back pain as well as improve athletic performance. With a strong commitment to customer service and security, DoMark plans to expand its marketing relationships across a far broader product set.
The management team has positioned the company to capitalize on emerging opportunities by working with the world's most forward-thinking companies to develop and market game-changing products with the promise of long-term financial growth. Leveraging the expertise of its team, the company continues to evaluate acquisition candidates and products targeting underserved markets to increase its growth potential. Disclaimer
DoMark International, Inc. Blog
DoMark International, Inc. News:
DoMark International Inc. Positions Itself for Substantial Growth
Investment in Game Changing New Multi-Media Games Product Developer Imagic Ltd by Smartphone Accessory Supplier DoMark International
DoMark International Announces Move to Protect Shareholders by Cancelling 50k Preferred Shares, 5.74M Common A Shares
Mabwe Minerals Inc. (MBMI)
The QualityStocks Daily Newsletter would like to spotlight Mabwe Minerals Inc. (MBMI). Today, Mabwe Minerals Inc. closed trading at $0.1999, even with yesterday's close, on 1,125 volume with 2 trades. The stock’s average daily volume over the past 60 days is 6,874, and its 52-week low/high is $0.0056/$0.25.
Mabwe Minerals Inc. (MBMI) is a U.S. based natural resources and hard asset company focused on the mining, logistics, and commercial sales of industrial minerals and metals, with a particular emphasis on barite. The company's operations are conducted through its Zimbabwe affiliate, Mabwe Mineral Zimbabwe (Private) Ltd. Transitioning into commercial production, MBMI's company fundamentals are well positioned with virtually no debt and key strategic partnerships in place.
Along with its affiliate, Mabwe Minerals Zimbabwe (Private) Ltd., an indigenous Zimbabwe company, the company owns 100% of the mineral & metal rights to Dodge Mine. The mine will be managed by the company's minority owned partner, WGB Kinsey & Company, Zimbabwe's most experienced mining & construction company representing four generations of Kinsey leadership. Management believes WGB Kinsey & Company has all the necessary equipment and management experience to efficiently perform all the mining operations at Dodge Mine.
The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc. Hydrothermal barite deposits throughout Dodge Mine represent the highest grade of new barite sources to be brought into commercial production in years. A third party oil & gas drilling sector geologist recently confirmed that the multiple barite deposits are considered "World Class" in quality and highly efficient to mine via open pit extraction following the barite veins and salvaging large percentages of barite within the halo zones via jigging systems.
With a continuing worldwide shortage of high-grade barite, Mabwe Minerals is in the right place at the right time. The company's current customer uses barite as a weighting agent in oil & gas drilling applications in the Gulf of Mexico, home to the largest concentration of active rigs in the world. Coupled with the recent massive discovery of oil & gas off the coast of neighboring Mozambique along with new drilling contracts expected in the region, MBMI is in an attractive geographical location to capture the expected demands of this emerging market. Moving from an exploration stage company into commercial barite production, Mabwe Minerals is well positioned to generate significant shareholder returns. Disclaimer
Mabwe Minerals Inc. Company Blog
Mabwe Minerals Inc. News:
Mabwe Minerals Shareholder Report Card
Mawbe Minerals Files SEC Form 10-K, Annual Report
Raptor Resources Holdings Inc. (RRHI)
The QualityStocks Daily Newsletter would like to spotlight Raptor Resources Holdings Inc. (RRHI). Today, The Aristocrat Group Corp. closed trading at $0.015, even for the day. The stock’s average daily volume over the past 60 days is 72,688, and its 52-week low/high is $0.0002/$0.0395.
Raptor Resources Holdings Inc. (RRHI) is a publicly traded holdings company focused on mineral resource acquisition, exploration, and development. The company currently has two subsidiaries: Mabwe Minerals Inc. (MBMI), a natural resources and hard asset company engaged in the mining and commercial sales of industrial minerals & metals with first focus on barite; and TAG Minerals Inc., a mineral & metal resource acquisition, exploration, and development company with first focus on alluvial surface gold.
Mabwe Minerals has been the focus of the parent company’s efforts the last two years to move into commercial barite production. RRHI shareholders share a common interest with MBMI shareholders in the success of Dodge Mine as the parent company owns 90M shares of MBMI. The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc.
TAG Minerals, along with its indigenous affiliate, TAG Minerals Zimbabwe (Private) Limited, is responsible for alluvial gold production along with the development of greenfield assets targeting bedrock gold and other potential metals & minerals. As MBMI is transitioning into commercial barite production, RRHI will now focus on building assets within TAG Minerals with the intent of moving into commercial production within the next 18 months. TAG Minerals will utilize the latest in Heavy Particle Concentrators (HPC-30/HPC-100) through its relationship with Extrac-TEC whose gold recovery and mineral separation technology captures up to 98% of alluvial gold down to 50 microns. The company is in early stage exploration evaluating potential alluvial sites to ensure they meet the company's criteria for commercial production. Coupled with MBMI's acquisition of WGB Kinsey & Company, TAG Minerals is well positioned to fast track into commercial production once the company has successfully completed its exploratory testing.
RRHI management continues to improve its balance sheet as reflected in the company's SEC 10k filing, including favorable reductions in the company's debt/liabilities and securing 54.4M shares and 14.4M warrants of RRHI from prior employees. The company is committed to growing its asset base in TAG Minerals moving forward. Disclaimer
Raptor Resources Holdings Inc. Company Blog
Raptor Resources Holdings Inc. News:
Mabwe Minerals Shareholder Report Card
Raptor Resources Holdings Files SEC Form 10-K, Annual Report
Today before the opening bell, Cardium Therapeutics announced that Institutional Shareholder Services, Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), the nation’s leading independent proxy advisory firms, each recommend that Cardium’s stockholders vote “FOR” all proposals in the proxy statement and recommends a “1 Year” advisory say on pay frequency with respect to the matters that will be considered at the company’s annual meeting scheduled for June 6, 2013.
“We are pleased that Glass Lewis and ISS, the leading independent proxy and corporate governance advisory firms whose recommendations are relied upon by institutional shareholders, have recommended in favor of all proposals contained in our recent proxy statement. Each of these firms recommend a vote “For” the following: (1) re-election our Class I Directors, Edward W. Gabrielson, M.D. and Lon E. Otremba; (2) approval of the compensation paid to our named executive officers; (3) approval of the sale of the Series A Convertible Preferred Stock; (4) approval of a reverse stock split (5) approval of an increase to authorized common stock; and (6) ratification of the selection of our independent auditors. Our Board of Directors encourages all stockholders to submit their proxies in support of the Company’s proposals,” stated Christopher J. Reinhard, Cardium’s Chairman and CEO.
Cardium’s proxy statement and any other materials filed by the company with the SEC can be obtained at the SEC’s website at www.sec.gov or from www.cardiumthx.com. Only stockholders who held the company’s common stock as of the record date of April 26, 2013 are eligible to vote at the annual meeting. As always, the proxy statement should be read carefully before making any voting decision.
Those who have questions about the upcoming, voting methods, or proxy materials should contact Cardium’s proxy advisor, Georgeson, at 888-219-832.
For more information, visit www.cardiumthx.com
DoMark International, a leading investment management company primarily focused on mass market accessory products for major smartphone and tablet suppliers, today provided investors with an update and review of its operations and future plans. The complete report from CEO Andrew Ritchie is presented below in its entirety.
IRCharger – Infrared/Solar Charger Case for the Apple iPhone and Samsung Galaxy:
DoMark’s innovative 100% owned IRCharger facilitates the charging of mobile and smartphones with twin built in lithium batteries and an infrared/panel. The IRCharger for Apple iPhones and Samsung Galaxy III and S4 will be launched on August 1st 2013. With 137 million Apple iPhone units and 216 million Samsung units sold last year, these are the world’s leading smartphone products. DoMark is currently negotiating distribution worldwide and has advance orders for 58,000 units from two major US distributors.
DoMark last week announced its purchase of a 29% ownership stake in Imagic Ltd., a privately held company, at a cost of $580,000 in cash and shares. Imagic is a developer of mobile accessory products. A detailed description of a low cost revolutionary accessory to enhance the use of all smartphones and tablets for games and other applications will be announced nearer to its launch date. It is planned to capture a large piece of multi-billion dollar global gaming hardware sales in the run up to Xmas 2013 following its trade launch in the next two months.
Having given consideration to the small size of this investment and the decision to concentrate the Company’s efforts on the massive mobile product growth market given the opportunity presented by the Imagic acquisition and other potential investments currently under review by the Board, the Directors have decided to seek to sell the investment in Barefoot Science at an early opportunity.
DoMark is also very pleased to announce that the appointment of global entrepreneur and industrialist, John Bentley (www.johnbentley.biz), as a Non-Executive Director of DoMark, is to take place in June. He is also a director of Imagic Ltd. and so will ensure a strong and continuing link between DoMark and Imagic for the future. His experience in the area of Internet TV, digital games, and online and mobile communications and services will assist DoMark both in selecting new investment acquisitions for future growth, and their supervision. It will continue to be your directors’ policy of strengthening the Board when appropriate in line with its new mobile industry strategy.
As part of the Company’s restructuring and move towards better corporate accountability, overheads and debts have been dramatically reduced with no outstanding law suits. Management has also cancelled all 50 million Preferred Shares along with 7.4 million Common Shares attached to a previous Victory Lane investment.
“I am extremely pleased with the progress made over the past few months in enabling the Company to position itself to bring about its mobile industry strategy with new and exciting products from which the Company may expect substantial growth and robust shareholder return in 2013 and beyond,” Mr. Ritchie concluded. “The ability to be able to administrate and arrange distribution of the Company’s products as one will both simplify and expedite their administration and promotion to the public.”
For more information, visit www.DoMarkIntl.com
Rainbow Coral is carving off an ever larger slice of the biosciences pie with each passing day via shrewd partnering with key product and medical technology innovators, as well as via their wholly-owned biotech subsidiary, Rainbow BioSciences, LLC, as the biotech sector alone climbs steadily upwards of some $89.8B in revenues for 2012 (Ernst & Young, Biotech Industry Report 2013).
A leading example of this growth strategy by RBCC occurred in late March this year, as the company moved to form a strategic JV with the developer of an incredible sustained release drug delivery technology for biologics and other sensitive drugs, TheraKine. The TheraKine sustained release delivery platform offers a host of tunable options for extended duration and localized controlled release, whether it’s a six-month linear release or even a quick burst followed by slow release. The drug delivery space is a vital vector for RBCC’s overall strategy and the TheraKine deal is a classic example of how the company is positioning shareholders to profit off the development and commercialization of such highly sought after technologies.
More recently (May 21), RBCC took an even bolder step to capture space in the burgeoning, $142B plus U.S. drug delivery market by opening talks with a potentially key player in the transdermal delivery space working on patch technology. Transdermal patches offer several benefits over typical oral and intravenous methods, ranging from vastly improved bioavailability and longer duration, to greater safety/efficacy (with fewer side effects) and more uniform plasma levels. With estimates on the domestic transdermal delivery space alone upwards of $31.5B in just two year’s time, this deal with a potential leader in the sector could pan out into some serious upside for RBCC investors, especially considering the company’s overall biotech footprint.
One of the company’s most important partners, Nano3D Biosciences (n3D), the developers of an incredibly powerful BioAssembler product line that does 3D cell culture, allowing for researchers to generate extremely lifelike tissues which are nearly identical to those naturally occurring in the body, recently announced (May 13) a major U.S. distribution agreement. One of the big scientific product distributors, MIDSCI out of St. Louis, is intent on pumping out BioAssembler units to the eager domestic cell culture market, which stretches across the life sciences arena from academic and biotech research, to government and pharma.
This distribution deal comes on the heels of last year’s signing of a JV agreement between n3D and Rainbow BioSciences to help develop/market the BioAssembler technology and occurs amid a mounting level of excitement over the far-reaching potential of n3D’s magnetic levitation technology since being featured in the widely-read science journal Nature. When you have the top science journal on the planet calling your technology “the future of cellular research,” that is more than a PR jackpot, it’s something that kicks open the door to unquantifiable opportunities in the sector. There has been a blazing firestorm of coverage since the Nature publication in April’s issue and one look at the technology leaves investors with little to ponder about the potential massive impact of being able to create 3D tissues in the lab.
RBCC is a small company with a solid niche already carved out via its partnerships and the Rainbow BioSciences subsidiary in a much larger field that is dominated by majors like Amgen and Bristol Myers Squibb. With constantly evolving plans in the works, like an upcoming strategic partnership with a Houston-based genomics company that has an amazing 11 NASA-licensed patents that would give RBCC a solid foothold in genetic testing/personalized medicine, the company is growth focused on the global stage with a keen eye on the domestic market.
The global market for just the top 10 drug delivery technologies is headed for around $81.5B by 2015 and RBCC is working with TheraKine to tap that huge capital flow by seeking out new licenses for TheraKine’s portfolio of patented, selective, tunable, and site-specific drug delivery technologies abroad (reported April 24). There are a bounty of overseas healthcare providers just waiting to be harvested by such an advanced sustained-release delivery platform and the addition of new licenses is the best way for RBCC to keep the TheraKine partnership vital.
For more information on Rainbow Coral Corp., visit www.RainbowBiosciences.com
GNCC Capital, a Nevada based gold and silver exploration and marketing company, holds a number of properties in Arizona that it plans to develop through the use of exploration, testing, and joint ventures. Their recently announced agreement to purchase the 1,840 White Hills gold exploration properties for $10 million represents an effective doubling in size of the company’s total holdings. The principal players in the company’s growth are its executive officers, Nicolaas Edward “Ted” Blom and Ronald Yadin Lowenthal:
• President & Chief Executive, Nicolaas Edward “Ted” Blom, has over 25 years of experience in mining and energy, with expertise in structured finance, commercial and legal transactions, and business development, and is a Chartered Secretary of the Institute of Chartered Secretaries and Administrators, London. In addition to his formal degrees, Mr. Blom has completed the Harvard Business School Program for Management Development and has a Diploma in Mineral Economics from Imperial College, London. Mr. Blom is a member of the Association of Mining Analysts in the United Kingdom. He has been a strategic advisor and consultant to global hedge funds and private equity funds on investments in energy and mineral plays, and has appeared in numerous television, radio, and press interviews as an independent expert in mining and energy.
Mr. Blom has consulted and explored projects and proposals involving most minerals found on the African continent, including gold, silver, nickel, platinum, manganese, aluminum, coal, graphite, diamonds, titanium, and chromium, and is currently mandated to execute capital raising, structuring, and implementation of projects in Africa exceeding $20 billion. He has won numerous awards.
• Executive Chairman, Ronald Yadin Lowenthal, is a specialist in corporate finance, in the structuring of IPOs, and in raising funds for mining exploration companies. In addition to his formal education, including an MBA from Wharton Graduate Division, Mr. Lowenthal has received extensive experience in international finance. He was a founding director of Incentive Holdings Ltd. and Incentive Securities Limited, a South African based financial services group. He also served as a financial consultant and as the compliance officer to family owned Lowenthal & Co, a South African based stock broking, corporate finance, and fund management company specializing in obtaining mining concessions for exploration, as well as assisting mining and other companies in obtaining quotations on the Johannesburg Stock Exchange. He also served as an International Merchant Banker with Scandinavian Bank in both London and in Singapore, Amex Bank in both London and in Hong Kong, Rothschild Intercontinental Bank in both London and in Hong Kong, and with European and American Bank in New York.
For more information visit www.gncc-capital.com
Today's Top 3
Penny Stocks Profile
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Announces Filing of Proxy Statement Supplement and New Annual Meeting Date
- Consorteum Holdings, Inc. (CSRH) Enters Partnership Agreement With KO Entertainment, Inc.
- Cardium Therapeutics, Inc. (CXM) Announces Generx Publication In Molecular Therapy
- DoMark International, Inc. (DOMK) Smartphone Accessory Supplier, Makes Major Investment in Promising New Multi-Media Games Product Developer Imagic Ltd
- GNCC Capital, Inc. (GNCP) Reaches Agreement to Acquire White Hills Gold Properties
- GlobalWise Investments, Inc. (GWIV) Adds Toshiba Business Solutions AZ/CO as New Channel Sales Partner
- International Stem Cell Corp. (ISCO) to Present at Two Upcoming Investor Conferences
- Loans4Less.com, Inc. (LFLS) CEOCFO Magazine Interview Highlights Solid Market Position
- Low Carbon Technologies International, Inc. (LWCTF) Plans to Announce 6 Month YTD Financials
- Mabwe Minerals Inc. (MBMI) Shareholder Report Card
- Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
- Rainbow Coral Corp. (RBCC) Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market
- Raptor Resources Holdings Inc. (RRHI) Mabwe Minerals Shareholder Report Card
- Solar Wind Energy Tower, Inc. (SWET) Receives Notice of Allowance of Patent titled "Atmospheric Energy Extraction Devices and Methods"
- StreamTrack, Inc. (STTK) Announces Alliance to Potentially Reach Over 300 Million Registered PPTV Users
- The Aristocrat Group Corp. (ASCC) Unveils Debut Spirits Brand RWB Vodka
- The Guitammer Company Inc. (GTMM) Teams Up With Warner Bros. and Legendary Picturesfor Summer Release of "Pacific Rim," From Oscar® Nominated Director, Guillermo del Toro
- VentriPoint Diagnostics Ltd. (VPTDF) Announces Closing of Private Placement and Proposed Issuance of Shares for Debt
- Viaspace, Inc. (VSPC) and AGRICORP Sign Joint Development Agreement for 12 MW Power Plant Co-located with 2,100 acre Giant King Grass Plantation in Nicaragua
- VistaGen Therapeutics, Inc. (VSTA) and Duke University Publish Results on Production of Functional 3D Human Heart Tissue